• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Aphena Pharma Solutions

    Cytovance Biologics

    Alcami

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Syngene

    Reed-Lane

    Emergent BioSolutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Regulatory Overhaul for Medical Devices

    Implications for the pharmaceutical industry.

    Regulatory Overhaul for Medical Devices
    Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20
    Though regulatory collaboration between pharmaceutical organizations and drug delivery providers has been encouraged within the drug device combination product market for some time, pharmaceutical businesses marketing their products in the European Union (EU) are generally not well-versed in medical device regulation. However, as the combination product market grows and new technological innovations are introduced in device products, it is more important than ever before to ensure that both the drug and device components of combination products are given equal attention when it comes to product safety and efficacy. The EU Medical Device Regulation (EU MDR) published in 2017 addresses this very concern by clarifying and tightening regulatory scrutiny for device components. Meanwhile, the EU In Vitro Diagnostic Regulation (EU IVDR) has implications for pharmaceutical companies producing companion diagnostics. The Dates of Application for these new regulations are May 2021 and May 2022 respectively, meaning that pharmaceutical businesses must review their product portfolio without delay.

    Drug Device Combination Products: A need for regulatory clarity
    In the EU, combination products are regulated as medicinal products if the drug component is principal and not ancillary to the function of the device; or as medical devices when the drug has an integral but ancillary function. For products that fall into the first category, pharmaceutical businesses principally refer to the Medicinal Product Directive 2001/83/EC (MPD) to ensure compliance for the drug component, but this directive contains little guidance in relation to the device component. In addition, the EU MDR’s predecessor, the Medical Device Directive 93/42/EEC (MDD), did not elaborate on the requirements for device components within combination products regulated under the MPD. This lack of direction and of a link between the two directives created a regulatory gap where device components (combination product regulated as a medicine) were subject to a lesser degree of scrutiny than stand-alone medical device products.

    Article 117: Demonstrating conformity of device components
    A new point of reference for pharmaceutical companies is Article 117 of the EU MDR, which provides an amendment to Annex I of the Medicinal Product Directive. Article 117 outlines specific requirements for the device component, which businesses must now adhere to for their combination products to be deemed compliant. Specifically, where a product is governed by the MPD, the marketing authorization dossier submitted by pharmaceutical companies should include proof of conformity of the device component if it is available. To demonstrate proof of conformity, they must include results of the assessment of the conformity of the device component, in accordance with the relevant general safety and performance requirements of Annex I of the MDR, within their EU declaration of conformity. A second option is to submit the relevant certificate issued by a Notified Body allowing the manufacturer to affix a CE marking to the medical device. However, if the conformity assessment is missing, and requires the involvement of a Notified Body, the applicant must be able to provide an opinion issued by a Notified Body designated under MDR for the type of device in question. This opinion aims to demonstrate that a conformity assessment for the device component has been performed by a designated medical device Notified Body against the relevant requirements of the EU MDR. Essential elements of conformity include technical documentation which demonstrates the safety, performance and clinical benefit of the device, and ongoing post-market surveillance activities (inclusive of Post-Market Clinical Follow-up as needed) conducted in conjunction with risk management and clinical evaluation.

    Pharmaceutical Companies: Elements to prepare for
    Many medicinal product manufacturers were unaware of MDD requirements for their drug device combination products, and are therefore largely unfamiliar with device regulation. They must seek and build up expertise in this area to tackle increased scrutiny of medical device safety and performance. There are multiple elements to this: learning how to interpret the regulation, correctly developing compliance documentation, and liaising with Notified Bodies. Without prior experience and the right skills, tackling these may be challenging as medical device companies have already invested time and resources to implement compliance processes. The device industry is currently keeping watch for Notified Bodies to be designated under the EU MDR, as there have only been thirteen designations so far. Pharma companies must follow suit and ensure they are liaising with a Notified Body that is waiting for, or has already received a designation for devices that are subject to conformity assessment under the EU MDR. A final crucial point is that manufacturers can benefit from a variable extended transition period for those drug device combination products already holding a CE Mark under the current MDD 93/42/EEC until their certificate expiry date, but no later than May 26, 2024. Businesses that opt for this extension must be aware that they cannot make changes to the products unless they are re-certified according to EU MDR 2017/745, and so it is advisable not to delay in achieving compliance. 

    Companion Diagnostics: A new addition in the EU IVDR
    The EU IVDR includes a new product category for companion diagnostics, which will now be under greater regulatory scrutiny as a result. ‘Companion diagnostic’ refers to a device which is essential for the safe and effective use of a corresponding medicinal product, and can help to identify before and/or during treatment patients who are most likely to benefit from the medicinal product; or patients likely to be at increased risk of serious adverse reactions as a result of treatment with the medicinal product. Though the transition period for the EU IVDR is longer, there are only three Notified Bodies that have been designated for IVD devices to date, and there are fewer organisations awaiting designation in comparison with the EU MDR. In addition to Notified Body timelines, companies are dependent on national Competent Authorities (or the European Medicines Agency) for reviewing the associated medicinal product. This needs to be built into compliance planning, which should also take into consideration the stricter scrutiny that companion diagnostics will be under as Class C devices (the EU IVDR’s classification system terms Class A as the lowest risk and Class D as the highest). As with the EU MDR, clinical evidence supporting the intended purpose of the devices is essential for compliance submission. Manufacturers must follow a performance evaluation plan, demonstrating the following three elements: scientific validity; analytical performance; and clinical performance. Where there is a lack of data, new clinical utility studies may be necessary, further extending the compliance process timeline.

    No Grandfathering: Evaluating product portfolios
    Under the new medical device regulations, grandfathering is not permitted, meaning that every medical device needs a new CE mark. There are significant business implications of this as companies that do not meet the deadlines risk losing market access until their products are compliant. Pharmaceutical companies working with contract organisations for device components must safeguard their product portfolio by ensuring that these organizations are compliant. Reviewing device compliance, whether internally or at a partner organization, may seem daunting for companies that are doing so for the first time. For this reason, it is recommended that combination product pharmaceutical companies, as well as pharmaceutical companies that present medicinal substances with a Companion Diagnostic, develop expertise and implement compliance processes that will facilitate future assessments and help to ensure regulatory compliance in the long-term. 
    Related Searches
    • Drug Delivery

    Related Features

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20

    • Drug Delivery
      Not Your Father’s Oral Thin Film

      Not Your Father’s Oral Thin Film

      A look at how oral film drug delivery is evolving.
      Rodolphe Obeid, Vice President of Operations, IntelGenx 06.04.20


    • Drug Delivery
      CEO Spotlight: Will Downie

      CEO Spotlight: Will Downie

      Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
      Tim Wright, Editor, Contract Pharma 04.01.20

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Delivery
      Nasal Drug Delivery

      Nasal Drug Delivery

      A look at best practices for testing nasal drug delivery devices
      Maria Smith, senior manager & Charles Shaw, scientific advisor, Renaissance Lakewood LLC 01.25.19


    • Drug Delivery | Drug Development
      Traveling Toward the Intersection of Drug Development and Delivery

      Traveling Toward the Intersection of Drug Development and Delivery

      Overcoming the challenges of delivering drugs to patients.
      Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems 06.12.18

    • Drug Delivery | Solid Dosage/Creams/Ointments
      FDCs on the Rise

      FDCs on the Rise

      Fixed-dose combination drugs continue to gain traction due to a multitude of benefits they offer, including speed to market a
      Betsy Louda, Associate Editor, Contract Pharma 03.09.18

    • Drug Delivery
      The Future of Inhaled Medications and Inhalation Technology

      The Future of Inhaled Medications and Inhalation Technology

      Formulations, devices and strategy through non-clinical development
      Simon Moore, Envigo 10.11.17


    • Drug Delivery
      Digital Drug Delivery: A Snapshot in Time

      Digital Drug Delivery: A Snapshot in Time

      Technology is transforming the future of drug delivery
      Sam Van Alstyne, 3M Drug Delivery Systems 10.11.17

    • Drug Delivery | Drug Development
      Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

      Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

      The challenges of using the lung as a portal for the treatment of systemic conditions
      Tugrul Kararli, Kurt Sedo, Josef Bossart, PHARMACIRCLE 10.11.16

    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16


    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16

    • Drug Delivery | Drug Development | Excipients | Process Development | Process Validation | Risk Management | Validation
      Process Development Trends

      Process Development Trends

      An approach to process development of pMDIs using cold fill and pressure fill technology
      Steve Haswell, 3M Drug Delivery Systems 05.05.16

    • Aseptic Processing | Biosimilars | cGMP Manufacture | Drug Delivery | Injectables | Parenterals
      Injectables: The New Oral?

      Injectables: The New Oral?

      The growth trend of injectables continues across the pharma landscape.
      Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC 04.05.16

    Trending
    • Integrated Continuous Manufacturing ICM
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login